Endovascular therapy of acute ischemic stroke: report of the Standards of Practice Committee of the Society of NeuroInterventional Surgery

K A Blackham, P M Meyers, T A Abruzzo, F C Alberquerque, D Fiorella, J Fraser, D Frei, C D Gandhi, D V Heck, J A Hirsch, D P Hsu, M Jayaraman, S Narayanan, C Prestigiacomo, J L Sunshine, on behalf of the Society for NeuroInterventional Surgery

ABSTRACT

Objective To summarize and classify the evidence for the use of endovascular techniques in the treatment of patients with acute ischemic stroke.

Methods Recommendations previously published by the American Heart Association (AHA) (Guidelines for the early management of adults with ischemic stroke (Circulation 2007) and Scientific statement indications for the performance of intracranial endovascular neurointerventional procedures (Circulation 2009)) were vetted and used as a foundation for the current process. Building on this foundation, a critical review of the literature was performed to evaluate evidence supporting the endovascular treatment of acute ischemic stroke. The assessment was based on guidelines for evidence based medicine proposed by the Stroke Council of the AHA and the University of Oxford, Centre for Evidence Based Medicine (CEBM). Procedural safety, technical efficacy and impact on patient outcomes were specifically examined.

RECOMMENDATIONS

1. The availability of intra-arterial therapy should generally not preclude the intravenous administration of recombinant tissue plasminogen activator (rt-PA) in otherwise eligible patients (American Heart Association (AHA) Class I, Level of Evidence A, Centre for Evidence Based Medicine (CEBM) level 1b, grade A–B). *

2. Treatment requires the patient to be at an experienced stroke center with rapid access to cerebral angiography and qualified interventionists (AHA Class I, Level of Evidence C, CEBM level 2C, grade C). *

3. Intra-arterial chemical thrombolysis is an option for the treatment of selected patients with major stroke of <6 h duration due to an occlusion of the middle cerebral artery and who are not otherwise candidates for intravenous rt-PA (AHA Class I, Level of Evidence B, CEBM level 2b, grade B). *

4. Intra-arterial chemical thrombolysis is reasonable for patients who have contraindications to the use of intravenous thrombolysis, such as recent surgery (AHA Class IIa, Level of Evidence C, CEBM level 4, grade C). *

5. Combination intravenous/intra-arterial therapy is reasonable in selected patients who present with major stroke of <4.5 h duration (AHA Class IIa, Level of Evidence B, CEBM level 2a, grade B).

6. Intra-arterial thrombus removal with the Penumbra aspiration system or Concentric MERCI clot retrieval device is reasonable in selected patients with major stroke where care has been initiated at <8 h duration although data regarding improvement of clinical outcomes is unclear (AHA Class IIa, Level of Evidence B, CEBM level 2a, grade B).

7. The usefulness of other endovascular devices is not yet established, but they may be beneficial and may be considered (AHA Class IIb, Level of Evidence C, CEBM level 4, grade C). *

8. The usefulness of endovascular treatment in the posterior circulation is not yet established, but it may be beneficial and may be considered, even beyond the 6–8 h time window typical for anterior circulation stroke (AHA Class IIb, Level of Evidence C).

* As already defined by the AHA guidelines for the early management of adults with ischemic stroke (Circulation 2007) and AHA statement regarding indications for the performance of intracranial endovascular neurointerventional procedures (Circulation 2009).1,2

INTRODUCTION

Stroke is the third leading cause of death in the USA, Canada, Europe and Japan. According to the American Heart Association (AHA) and the American Stroke Association, there are now 795 000 new strokes that occur each year, resulting in 200 000 deaths, or 1 of every 16 deaths, per year in the USA alone. Ischemic stroke accounts for more than 80% of the total while hemorrhagic stroke accounts for the remainder. Stroke is the leading cause of adult disability in North America4 and the primary cause for inpatient Medicare reimbursement for long term adult care.6 The National Institutes of Health estimates that stroke costs now exceed $62 billion in US healthcare dollars per year.7 There are varying estimates as to potential numbers of ischemic stroke patients that might benefit from endovascular therapy but many expect an expansion of the number of patients treated with these techniques.8,9

The purpose of this document is to define the existing scientific basis for endovascular acute
ischemic stroke (AIS) treatment. The discussion of what constitutes adequate training and experience in endovascular surgical neuroradiology, both cognitive and technical, has been published elsewhere. In addition, national professional organizations have published performance and training standards for cervicocerebral angiography. Quality improvement guidelines for adult diagnostic cervicocerebral angiography have also been formally adopted by professional specialty societies. Adherence to these standards and guidelines is a prerequisite and fundamental for any interventional stroke treatment procedure.

Guidelines for performance of endovascular ischemic stroke therapy represent a multidisciplinary effort to reduce death and disability from this condition. These guidelines intend to encompass the training and experience of all physicians involved in the care of patients with cervicocerebral vascular disease regardless of medical specialty. In developing the present recommendations, the writing group conducted a systematic review of English language literature published between January 1998 and January 2011 to evaluate the evidence supporting the endovascular treatment of AIS, as well as incorporating already existing guidelines published by the AHA. The writing group has applied the rules of evidence and formulation of strength of recommendations used by other AHA guideline panels, and by the University of Oxford, Center for Evidence Based Medicine (CEBM). Procedural safety, technical efficacy and impact on patient outcomes were specifically examined.

Endovascular therapy for patients with AIS is an area of intense investigation and brisk technological development. This, in combination with the fact that the outcome of AIS may depend on numerous variables, such as thrombus type, location and clot burden, individual patient parameters like age, collateral circulation and underlying comorbidities, as well as time to treatment, unfortunately restricts the availability of standardized outcomes research. Intra-arterial (IA) thrombolysis has been studied in two randomized trials and numerous case series and is endorsed by national organizations as an acceptable alternative stroke therapy, in selected patients. In the past decade, two devices received Food and Drug Administration (FDA) approval for safety and efficacy in endovascular thrombus removal. Several other devices, drugs and other reperfusion strategies are used off-label or are in development with the goal of obtaining the most rapid and complete recanalization possible, while minimizing vascular damage and hemorrhagic complications.

**INTRAVENOUS THROMBOLYSIS**

The availability of intra-arterial therapy should not preclude the intravenous administration of recombinant tissue plasminogen activator (rt-PA) in otherwise eligible patients (AHA Class I, Level of Evidence A, CEBM level 1b, grade A–B).

At present, the only therapy demonstrated to improve clinical outcomes from AIS in randomized controlled clinical trials is thrombolysis of the clot responsible for the ischemic event. Specifically, since 1996, intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is FDA approved for the treatment of ischemic stroke to patients without evidence of hemorrhage seen on initial non-contrast head CT, if treatment is initiated within 3 h of a clearly defined symptom onset. A 2009 scientific advisory from the AHA/American Stroke Association recommended extension of the time window for treatment with IV rt-PA to 4.5 h, largely based on the prospective, randomized, placebo controlled European Co-operative Acute Stroke Study III (ECASS III) trial. rt-PA is administered intravenously at a dose of 0.9 mg/kg (maximum of 90 mg) with 10% of the total dose given as a bolus with the remainder infused over 60 min. This dosage has been shown to be safe and effective in routine clinical use, with results comparable with pooled, randomized, controlled trial data in the Safe Implementation of Thrombolysis in Stroke—Monitoring Study (SITS-MOST), a large observational registry. As noted below in the section on combination therapy (IV plus IA rt-PA), several trials and case series have shown that patients with a large clot burden are not likely to achieve recanalization with IV rt-PA. A 2011 retrospective review of 138 patient treated with IV rt-PA demonstrated that of the 76 patients who did not achieve recanalization, the majority had clot lengths which exceeded 8 mm. Clot length was determined via automated measurements of vascular hyperdensity on thin section pretreatment CT scans. The remaining patients who did achieve recanalization had clot lengths of <8 mm.

**ENDOVASCULAR TREATMENT**

Treatment requires the patient to be at an experienced stroke center with rapid access to cerebral angiography and qualified interventionists (AHA Class I, Level of Evidence C, CEBM level 3c, grade C). Endovascular treatment of stroke requires the infrastructure to support the rapid assessment, stabilization and transport of patients with AIS, along with documented procedures for communication with the receiving hospital emergency room and stroke team. Evaluation of the patient before and after the procedure requires a multidisciplinary team approach not only for discussion of endovascular treatment options, particularly on full evaluation of the underlying vascular disease, but also for evaluation and treatment of the attendant complications. Nursing and technological staff should have training in endovascular procedures and should be available on a continuous basis with a 60 min response time to the hospital. There should be documentation and evaluation of procedural indications, outcomes and complications with the support of a quality assurance program. This brief description of an experienced stroke center is subsumed within the more detailed evidence based guidelines describing the concept of a Comprehensive Stroke Center (CSC), defined by the Brain Attack Coalition in 2005 as a facility or system that is able to “diagnose and treat stroke patients who require a high intensity of medical and surgical care, specialized tests or interventional therapies”. The CSC is the highest level of stroke care within the auspices of larger ‘stroke systems of care’, as advocated by the American Stroke Association.

A Center for Disease Control and Prevention evaluation of data from the 2005–2007 Paul Coverdell National Acute Stroke Registry recommends that coordinated stroke programs and surveillance of performance measures are needed in order to improve adherence to measures that improve the quality of care. The ‘Get With The Guidelines’ stroke program of the AHA is a national stroke quality improvement program developed to reduce disparities in acute stroke care. Voluntary cooperation with this program is associated with substantial and sustained improvement in hospital based acute stroke care regardless of hospital size, geography and teaching status. Since the original publication of Primary Stroke Center recommendations in 2000, there have been over 800 facilities certified by the Joint Commission and improved outcomes have been validated by several studies evaluating the stroke systems of care.
INTRA-ARTERIAL THROMBOLYSIS

Intra-arterial thrombolysis is indicated for the treatment of selected patients with major stroke of <6 h duration due to an occlusion of the middle cerebral artery (AHA Class I, Level of Evidence B, CEBM level 2b, grade B).

Intra-arterial thrombolysis is reasonable for patients who have contraindications to the use of intravenous thrombolysis, such as recent surgery (AHA Class IIa, Level of Evidence C, CEBM level 4, grade C).

IA thrombolysis provides a supplement or alternative to IV thrombolysis in carefully selected patients with AIS. Delivery of fibrinolytic agents directly into the thrombus permits administration of a smaller dose of the agent, which theoretically decreases the risk of cerebral and systemic hemorrhagic complications from systemic effects. This concept led to studies that were designed to explore an extension of the treatment window beyond the relatively short therapeutic window for IV rt-PA. Two randomized, multicenter, controlled trials of IA thrombolysis in acute middle cerebral artery stroke have been completed—the Prolyse in Acute Cerebral Thromboembolism Trial I (PROACT-I) and PROACT-II. Recanalization efficacy and safety of IA recombinant pro-urokinase (r-proUK) for middle cerebral artery occlusion of 6 h duration was demonstrated in the PROACT-I trial. PROACT-II demonstrated a 15% absolute increase in good outcome. The results of PROACT-II, although encouraging, were insufficient to secure FDA approval of r-proUK for an acute stroke indication. For this reason, IA thrombolysis using any thrombotic agent still represents an off-label use of r-proUK or rt-PA. The clinical benefits observed in the PROACT II study were confirmed in a recent meta-analysis of five randomized IA therapy trials, which included PROACT I, and the prematurely halted Japanese Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELIT) trial, which also found higher rates of good and excellent clinical outcomes in patients undergoing IA therapy. In addition, several studies have suggested that successful recanalization correlates with improved clinical outcomes in patients with AIS secondary to large vessel occlusion. Retrospective studies have shown that IA thrombolysis within 5 h is possible at experienced stroke centers and does not significantly increase risk in patients who have contraindications to IV thrombolysis, as recent surgery. The AHA/American Stroke Association Council endorses IA thrombolysis as an acceptable stroke therapy in major stroke of <6 h duration due to an occlusion of the middle cerebral artery in patients ineligible for IV thrombolysis.

COMBINATION TREATMENT

Combination intravenous/intra-arterial therapy is reasonable in selected patients who present with major stroke of <4.5 h duration (AHA Class IIa, Level of Evidence B, CEBM level 2a, grade B).

IV thrombolysis has the advantage of ease and efficiency of administration while IA thrombolysis has the potential for superior recanalization, particularly in proximal occlusions. Combining the two techniques was studied in the 1999 Emergency Management of Stroke (EMS) Bridging Trial and the Interventional Management of Stroke (IMS) studies I and II, published in 2004 and 2007, respectively. The results of IMS II confirmed the safety and increased recanalization rates initially observed in the EMS bridging trial. In IMS I, patients were administered two-thirds dose IV rt-PA followed by IA rt-PA administration. This approach yielded favorable outcomes in 33% of subjects which was significantly greater than the outcome of the historical control group (the placebo arm from the National Institute of Neurological Disorders and Stroke (NINDS) trial) but not significantly different from the historical purely IV thrombolysis group. Both IMS I and II found that IV therapy alone rarely achieved recanalization of large vessel occlusion. Several case series have supported these findings. Currently, a larger phase III, randomized, controlled IMS III trial is comparing the combined IV/IA approach to standard IV rt-PA therapy alone. Due to the intervening development and FDA clearance of new devices, IA treatment in IMS III allows the use of the EKOS ultrasonic microcatheter (which was used to augment thrombus fragmentation in IMS II), the Penumbra thrombo-assembly system as well as the Concentric MERCI clot retriever device. A recent meta-analysis investigated the use of IA thrombolysis after full dose IV tPA (0.9 mg/kg) and suggested that this method of combined treatment is safe and associated with higher recanalization rates and better functional outcome at 3 months.

ENDOVASCULAR THROMBUS REMOVAL

Intra-arterial thrombus removal with the Penumbra aspiration system or Concentric MERCI device is reasonable in selected patients with major stroke where care has been initiated at <8 h duration although data regarding improvement of clinical outcomes is unclear (AHA Class IIa, Level of Evidence B, CEBM level 2a, grade B).

Rapid clot extraction enabling prompt cerebral reperfusion has obvious appeal as a technique for ischemic stroke treatment. This treatment is theoretically ideal for those occlusions of cardioembolic origin, with well organized platelet poor thrombus and extensive fibrin cross linking that is refractory to chemical lysis. The two FDA cleared devices for endovascular clot removal are the MERCI Retrieval System (Concentric Medical Inc, Mountain View, California, USA) and the Penumbra stroke system (Penumbra Inc, Alameda, California, USA). The MERCI device was specifically designed and tested for extracting clots from major cerebral arteries, such as the distal internal carotid artery, the M1 segment of the middle cerebral and the vertebrobasilar arteries. Clots located in more distal cerebral arteries, like the posterior cerebral arteries, distal segments of the middle cerebral arteries or the anterior cerebral arteries are usually not accessible with the MERCI device and the risks of aggressive distal cerebrovascular instrumentation may not be justified by the potential clinical benefit. The safety and efficacy of the MERCI retrieval device for thrombus retrieval was tested in two prospective, single arm, multicenter trials conducted in the USA and led to FDA approval for clot retrieval in the presence of acute stroke. However, the approval has been criticized by stroke specialists because neither of the two conducted clinical trials evaluating the MERCI retrieval device were designed to prove its clinical efficacy for stroke therapy. Similarly, the Penumbra pivotal trial was a prospective, single cohort, phase 2 study to evaluate the safety and effectiveness of the Penumbra system aspiration catheter in 125 patients with moderate to severe acute stroke due to large vessel occlusion. The FDA approved Penumbra system is an aspiration catheter with a clot separator wire. While the study results showed an unusually high rate of recanalization, only 25% of patients had a good 90 day clinical outcome as defined by a modified Rankin Scale score of ≤2, an outcome that is no better than the natural history of untreated acute stroke patients. Subsequent pooled analysis of the MERCI data, however, found that target vessel recanalization was the strongest predictor of outcomes, which corroborates findings in IMS I and II.
OTHER ENDOVASCULAR APPROACHES

The usefulness of other endovascular devices is not yet established, but they may be beneficial and may be considered (AHA Class IIb, Level of Evidence C, CEBM level 4, grade C).

Angioplasty alone and stent assisted angioplasty have been described, in retrospective series, for the past decade in the treatment of acute cerebral stroke, more recently using existing self-expanding stents approved for stent assisted coil embolization and intracranial atherosclerosis.52–55 Despite a relatively high technical success rate, there are potential immediate and delayed complications of permanent stent placement in acute stroke. The additional risk of hemorrhagic stroke transformation with ongoing antiplatelet therapy is not well defined. Likewise, the incidence of in-stent restenosis, which affects at least 30% of cerebral arteries stented for intracranial atherosclerosis, is not known for intracranial stents implanted for recanalization of acute thrombus.56 A single arm, prospective, FDA approved trial, Stent Assisted Recanalization in Acute Stroke (SARIS), reported data in 20 patients that supports the relative safety and angiographic efficacy of primary stenting in acute stroke.57 Closed cell stent designs allow for resheathing of self-expanding stents, after partial or even full deployment, resulting in a retrievable stent that functions to restore flow temporarily.58 While this may represent a new direction for acute stroke intervention, the concurrent use of antiagulant, antiaggregating and thrombolytic medications requires further investigation before the routine implementation of this treatment strategy.

POSTERIOR CIRCULATION

The usefulness of endovascular treatment in the posterior circulation is not yet established, but it may be beneficial and may be considered, even beyond the 6–8 h time window typical for anterior circulation stroke (AHA Class IIb, Level of Evidence C).

Recanalization rates and outcomes in basilar artery occlusion vary widely for both IA and IV thrombolysis, which is likely due to the wide clinical presentation and differing mechanisms and severity of underlying disease.59 Although occlusion of the basilar artery accounts for only 6–10% of large vessel strokes in humans, several meta-analyses have found that failure to recanalize an occluded basilar artery almost universally results in a poor clinical outcome.59 60 Failure of recanalization, coma at presentation, as well as a proximal location of thrombus have been found to be associated with higher mortality rates.61 Recanalization rates of over 50% have been achieved with both IA and IV thrombolysis in meta-analyses of multiple case series.62 63 A single large prospective registry, the Basilar Artery International Cooperation Study (BASICS), found that in an analysis of 592 patients, 38% of patients were treated >7 h after ictus either with antithrombotics, IV thrombolysis or IA therapy. In this cohort of patients, endovascular therapy did not show superiority over IV thrombolysis in terms of mortality or dependency, after adjusting for multiple factors such as age, stroke severity score and location of the occlusion.65 In the clinical trials of the MERCI and Penumbra thrombus removal devices, posterior circulation occlusions were included and treated with the same time parameters as the anterior circulation occlusion (up to 8 h following ictus) and were found to have similar recanalization rates.20 21 Due to the relatively rare nature of basilar artery occlusion, the poor prognosis and the paucity of prospective data, the rationale for aggressive treatment has been based largely on expert opinion, case series and meta-analyses.64

ADJUNCTIVE THERAPY

Systemic anticoagulation with heparin reduces the risk of catheter related embolism and augments the thrombolytic effect of some agents such as the now infrequently used r-proUK. Another rationale for antithrombotic therapy is prevention of acute re-occlusion. These indications are counterbalanced by the potentially increased risk of brain hemorrhage when heparin is combined with a thrombolytic agent. There is no standard heparin regimen established for IA thrombolysis in acute stroke. Data from the MultiMERCI trial indicates that rates of hemorrhage were not increased when heparin was used.65 PROACT-I18 reported a 27% rate of symptomatic brain hemorrhage with a heparin regimen of 100 U/kg bolus and 1000 U/h for 4 h used with 1A r-proUK. Subsequently, a low dose heparin regimen was used in the PROACT studies (2000 U bolus and 500 U/h for 4 h), which reduced the symptomatic brain hemorrhage rate to 7% in PROACT-I and to 10% in PROACT-II.19 GP IIb/IIIa inhibitors have never been studied in a randomized trial of IA thrombolysis in acute stroke but have been used anecdotally to treat re-occlusion and may be necessary during stent placement in the treatment of acute stroke, although dosing and route of administration are variable. A randomized, dose escalation study of IV abciximab in AIS (not exceeding approved doses for coronary intervention) suggested relative safety up to 24 h after onset, although there were non-dose related asymptomatic intracranial hemorrhages.66 Use of the IIb/IIIa inhibitor abciximab for the IV treatment of acute stroke did not demonstrate either safety or efficacy compared with placebo in the phase III trial, Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II).57

THROMBLYTIC AGENTS

All thrombolytic agents are plasminogen activators and convert plasminogen to its active agent plasmin. rt-PA (alteplase) and r-proUK are the best characterized in the treatment of AIS.18 19 23 Newer agents such as tenecteplase, reteplase, plasmin and microplasmin, and combination therapies to improve efficacy of clot lysis (fibinolytics and GP IIb/IIIa agents, and fibrinolitics and direct thrombin inhibitors) remain investigational.68–70 Desmoteplase, a fibrin selective plasminogen activator, initially thought to have promise as an IV thrombolytic, showed no benefit over placebo in a phase III trial targeting an imaging defined ischemic penumra.71 Although some drugs may have differences in systemic effects and hemorrhagic complications, it remains unknown whether one thrombolytic agent is superior to another in terms of revascularization of AIS. Only IV rt-PA is FDA approved for the treatment of acute stroke and all thrombolytics are off-label when administered IA.

IMAGING

Imaging recommendations for treatment of acute stroke are included in the AHA guidelines for the early management of adults with ischemic stroke.1 Imaging is a class I recommendation and in most cases a non-contrast head CT will provide sufficient information to guide emergent management decisions; the initial imaging evaluation is required to exclude the presence of hemorrhage or other mass lesion mimicking ischemic stroke.72 There is no Class I evidence not to treat based on other CT findings, although some findings have been associated with poorer outcomes, such as the Alberta Stroke Program Early CT Score (ASPECTS), which has been shown to predict outcome in thrombolysis treated stroke patients with signs of acute ischemia on CT.73 The acquisition of vascular imaging, whether
CT angiography or MR angiography images with concomitant perfusion imaging during acute stroke, has been shown to be achievable in a reasonable time frame (<15 min imaging time for MRI; 10 min for CT). CT angiography and MR angiography can be useful to triage patients in terms of large vessel versus small vessel disease and, therefore, to amend treatment options. For this reason, the availability of multimodality vascular imaging in acute stroke has been suggested as a quality metric for a CSCI. Using CT or MR perfusion to identify patients with a mismatch of infarct core and ischemic penumbra, in theory, may allow improved patient selection and/or extension of current treatment time windows and is currently an intense area of research.

The Diffusion and Perfusion Imaging Evaluation for Under-standing Stroke Evolution (DEFUSE) investigators noted significant increased odds of achieving a favorable clinical response in patients with MRI defined perfusion/diffusion mismatch treated with IV thrombolysis in the 3–6 h window. However, Desmoteplase in Acute Ischemic Stroke Trial II (DIAS-II), the only randomized trial using an ischemic penumbra defined by perfusion imaging to select patients for IV thrombolysis, failed to demonstrate benefit of desmoteplase over placebo in the 3–9 h window.

In 2010, a technology assessment subcommittee of the American Academy of Neurology concluded that there was insufficient evidence to support the routine use of perfusion imaging in the triage of acute stroke patients in the diagnosis of acute stroke. Current evidence states that diffusion weighted imaging is superior to CT for the diagnosis of AIS and indicates that, in anterior circulation stroke, the initial infarct core volume is the best predictor of response to acute stroke therapy.

Studies designed to determine defining thresholds for futile revascularization and poor outcome have indicated that an ASPECT score of ≤7 and a diffusion weighted imaging core infarct volume of ≥70–100 ml are more frequently associated with poor clinical results.

CONCLUSION
AIS secondary to large vessel occlusion is a potentially devastating disease for which best treatment remains elusive. Recanalization efficacy and safety has been shown for IA thrombolyis and some thrombectomy devices. Randomized controlled trials have demonstrated clinical efficacy for IA thrombolyis in selected patients with acute middle cerebral artery occlusion. The desire to promote and popularize existing treatment options and exciting new devices or techniques must be tempered by the realization that the clinical efficacy of some treatment methods remains incompletely understood and warrants ongoing scientific and clinical research. To promote best possible clinical practice, the administration of interventional stroke treatment should remain in the hands of experienced stroke experts who should maximize data collection to achieve the best possible patient outcomes.

Author affiliations
1Department of Radiology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio, USA
2Department of Radiology and Neurological Surgery, Columbia University, College of Physicians and Surgeons Director, Neuroendovascular Service New York Presbyterian - Columbia, Neurological Institute of New York, New York, USA
3University of Cincinnati Medical Center, Cincinnati, OH, USA
4Division of Neurological Surgery, Barrow Neurological Associates LTD, Phoenix, AZ, USA
5Department of Neurological Surgery, Stony Brook University Medical Center, Stony Brook, New York, USA
6Department of Neurological Surgery, University of Kentucky, Lexington, KY, USA
7Interventional Neuroradiology, Radiology Imaging Associates, Englewood, CO, USA
8Department of Neurological Surgery, UMDNJ-New Jersey Medical School, Newark, NJ, USA
9Department of Radiology, Forsyth Radiological Associates, Winston Salem, NC, USA
10Neuroradiological Radigology, Massachusetts General Hospital, Boston, MA, USA
11Warren Alpert School of Medicine at Brown University, Director, Interventional Neuroradiology, Rhode Island Hospital, USA
12Departments of Neurosurgery and Neurology, Wayne State University/Detroit Medical Center, Detroit, MI, USA
13Department of Neurological Surgery, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA

Acknowledgments The authors would like to thank and acknowledge all members of the SNIS Executive Committee for their review and endorsement of this guidelines document.

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.

REFERENCES


Corrections


The following author’s details should be read: Albuquerque FC, Barrow Neurosurgical Associates LTD, Phoenix, AZ, USA.


The following author has been added to the author list: Dr. Muhammad Shazam Hussein


This article was published with the incorrect doi number. The correct doi number is: doi:10.1136/jnis.2010.003004.
ORIGINAL RESEARCH

Stent assisted coiling of the ruptured wide necked intracranial aneurysm

Y M Lodi,1,2 J G Latorre,3 Z El-Zammar,3 A Swarnkar,2 E Deshaies,1,2 R D Fessler4

ABSTRACT

Background Stent assisted coiling of unruptured wide necked intracranial aneurysms require antiplatelets to prevent stent thrombosis. The effect of the loading dose of antiplatelets prior to the stent coiling procedure in an unsecured wide necked ruptured intracranial aneurysm is not known.

Objective To report any potential complication associated with the use of both aspirin and clopidogrel in stent assisted coiling of ruptured wide necked intracranial aneurysms.

Methods Consecutive patients who underwent stent assisted coiling for ruptured wide necked intracranial aneurysm were enrolled from 2005 to 2009. Patients’ demographics, including Hunt and Hess grade, Fisher scale, and location and size of aneurysms, were collected. Complications such as rupture of aneurysm, thromboembolic events, ventriculostomy associated or systemic hemorrhages were recorded. Additionally, a 90 day outcome measurement was obtained using the Glasgow Outcome Scale.

Results 22 patients with a mean age of 50±13 years underwent stent assisted coiling. A loading dose of clopidogrel 300 mg and aspirin 325 mg orally were given prior to stent placement. There was no intraoperative rupture of aneurysm, ventriculostomy associated hemorrhage or systemic hemorrhagic event. There were two episodes of stent thrombosis; one was an asymptomatic event which developed during the stent assisted coiling procedure and resolved spontaneously; the other was symptomatic which required intra-arterial administration of glycoprotein IIbIIIa receptor antagonist. There was no mortality and good outcome was observed in 82% of patients.

Conclusion In our series of carefully selected patients, therapeutic dual antiplatelet loading prior to stent assisted coiling of ruptured wide necked intracranial aneurysm was not associated with increased bleeding complications. However, thromboembolic events remain the main challenge. Further study is required to confirm the safety of antiplatelet loading in stent assisted ruptured intracranial aneurysm coiling.

INTRODUCTION

The challenges of stent assisted treatment of complex intracranial aneurysm have been described in previous studies. Most of the data1–9 came from experiences of using Neuroform stents (Boston Scientific Target, Fremont, California, USA) which were approved by the Food and Drug Administration in 2002 under humanitarian device exemption. The Enterprise stent (Cordis Neurovascular, Miami, Florida, USA) is a relatively new intracranial stent approved by the Food and Drug Administration in 2007 under the guideline of humanitarian device exemption for the treatment of wide necked intracranial aneurysm. The uses of these types of stents have been associated with technical challenges, including difficulties in navigation of stent, imprecise placement of stent and stent migration.1–10 The technical challenge in navigation of stent in the intracranial circulation varies from 3% to 14.2%, and the incidence of stent migration ranges from 1% to 16%. The clinical complications associated with stents include intraoperative rupture of aneurysm and immediate or delayed thromboembolic events associated with stent.1–8 10 The most common clinical complication is transient or permanent thromboembolic event related to intracranial stent, the incidence of which varies from 2% to 21%. The second most common clinical complication is intraoperative rupture of aneurysm and hemorrhage that varies from 1.5% to 15%. Most of the patients enrolled in the previous studies had unruptured wide necked aneurysms and the numbers of ruptured intracranial aneurysm patients were very small. However, two recent studies11 12 enrolled many ruptured wide necked aneurysms but the results varied. Recently, two studies13 14 deliberately evaluated the risk and benefit of stent assisted repair of ruptured intracranial aneurysms. In both studies13 14 there was no preoperative standard antiplatelet regimen using aspirin and clopidogrel for the protection of stent. However, in one,13 glycoprotein IIbIIIa receptor antagonist was administered in a minority of patients prior to stent deployment.

Currently, there is no single study that has specifically used an antiplatelet regimen (both aspirin and clopidogrel) prior to the deployment of stent or evaluated the antiplatelet effect on hemorrhagic and thromboembolic complications in ruptured intracranial wide necked aneurysm. The objective of our study was to evaluate the safety, feasibility and outcome of patients who were treated with therapeutic doses of both aspirin and clopidogrel prior to stent assisted coiling of their ruptured intracranial aneurysm. Additionally, we tried to evaluate any hemorrhagic complications associated with the use of antiplatelets and placement of external ventricular drainage (EVD) catheter in our series.

METHODS

Data of patients undergoing stent assisted treatment of intracranial wide necked and fusiform aneurysms were prospectively collected and...
maintained in a database. Twenty-two consecutive patients who underwent stent assisted coiling of an intracranial ruptured wide necked aneurysm were selected and their data were retrospectively analyzed. Institutional Review Board approval was obtained prior to the treatment and retrieval of the data. The decision regarding surgical clipping versus endovascular stent assisted treatment of the aneurysm was made on the agreement between a vascular neurosurgeon and a neuroendovascular specialist. Additionally, prior to the selection of stent assisted repair, the treating endovascular operator thoroughly evaluated the architecture of the parent artery and ruled out any perceived difficulties in navigations through the blood vessels and catheterizations of the aneurysm.

The clinical severity of subarachnoid hemorrhage was assessed using the Hunt and Hess (H&H) grade, and the radiographic grade was measured using the Fisher scale. Outcomes were predefined on the basis of radiographic and clinical criteria. Radiographic outcomes were defined as the rate of immediate occlusion (complete occlusion (100%), near complete occlusion or neck remnant (>95% but <100%) or subtotal occlusion (<95%) after stent assisted coiling of the ruptured aneurysm. Clinical outcomes were measured using the Glasgow Outcome Scale (GOS). Outcome was defined as good if the obtained GOS was \( \geq 4 \) at the 90 day follow-up visit.

Wide necked aneurysm was defined as having a dome to neck ratio \(< 2\) or a neck \(> 4\) mm in diameter. All patients with a ruptured aneurysm who underwent stent assisted repair were treated with both a loading dose of aspirin 325 mg and clopidogrel 300 mg at least 2 h prior to intended stent deployment. Patients were continued on both aspirin 325 mg and clopidogrel 75 mg daily for 4 weeks after the stenting procedure and thereafter on daily 325 mg aspirin alone.

An EVD was placed if indicated prior to the procedure and initiation of antithrombotic medications to prevent potential bleeding complications related to ventriculostomy insertion. We also avoided postprocedural intravenous anticoagulation in subarachnoid hemorrhage patients to prevent potential bleeding complications associated with the ventriculostomy catheter. However, standard subcutaneous anticoagulation for the prevention of deep venous thrombosis was continued.

Procedures
Stent assisted coiling techniques have been described previously by us.\(^7\) \(^15\) \(^18\) Briefly, a 6 F guiding catheter (Boston Scientific Target, Fremont, California, USA) flushed with continuous heparinized saline was placed in the proximal part of the vessel of interest (internal carotid, vertebral artery) and advanced through the guiding catheter under the guidance of fluoroscopy and roadmaps. The aneurysm was crossed with a microcatheter (SL 10; Boston Scientific Target) and a microwire (Synchro soft 14; Boston Scientific Target). The microcatheter was swapped with an exchange length microwire (X-celerator 300 cm; eV3, Irvine, California, USA). Stent delivery system was prepared and advanced over the exchange length microwire as a unit and subsequently deployed across the neck of the aneurysm. Recently, we had begun to use a direct approach in which a 200 cm 0.014 compatible microwire was back loaded through the stent delivery system and the stent delivery system was then advanced as a unit through the guiding catheter. For the Enterprise stent (Cordis Neurovascular), a 14 compatible microcatheter (Prowler select 14; Boston Scientific Target) was loaded over the microwire (Synchro 14; Boston Scientific Target) which was placed on the parent artery distal to the neck of the aneurysm. Placement of the microcatheter was confirmed with a microcatheter angiogram. Baseline serum activated coagulation time was obtained, and intravenous heparin was administered after placement of the stent delivery catheter in the parent artery distal to the aneurysm and just 5–10 min prior to stent delivery to achieve an activated coagulation time of 1.5 times the baseline value. To cover the neck of the aneurysm adequately, the stent was deployed at least 4 mm proximal and 4 mm distal to the neck of the parent artery. The aneurysms in this series were catheterized by the direct approach in which the microcatheter was advanced through the interstiches of the Neuroform stent and Enterprise stent over a soft 14 compatible microwire (Synchro soft 14; Boston Scientific Target). Angiographic and clinical follow-up was planned for each patient at 3, 12, 18 and 56 months.

Statistical analysis
Patient demographics, including age, race, gender, cardiovascular risk factors, and location and size of aneurysm, were collected. A Student’s t test of independent samples was performed to compare means, and either a Pearson \( \chi^2 \) test or Fisher’s exact test was used to compare proportions. Univariate analysis was done to determine if there were clinical or patient characteristics associated with thromboembolic complications. Due to the low number of observed outcomes, multivariable analysis was not performed. All analyses were carried out using statistical software SAS V9.1.3.

RESULTS
Twenty-two patients with a mean age of 50±13 years underwent successful stent assisted coiling of ruptured wide necked intracranial aneurysms using 24 intracranial stents (Neuroform 14, Enterprise 10) (figures 1 and 2). The majority of the patients were female (19/22) and basilar artery bifurcation aneurysm was present in 11 (50%) cases. A presenting H&H clinical grade I was observed in 11 patients, grade II in three patients, grade III in four patients and grade IV in four patients. A history of hypertension was present in 10/22, active smoking history in 11/22 and a history of prior intracranial aneurysm was present in one patient. In our series, antplatelet loading with clopidogrel 300 mg and aspirin 325 mg was given at least 2 h and not more than 3 h prior to stent deployment. Fifteen patients required EVD placements—in 13 cases the EVD was placed at least 6 h before the procedure and antithrombotic loading dose while in two cases the EVD was placed after the procedure and antithrombotic loading dose, one on the same day and the other on postoperative day 2. There was no intraoperative rupture of aneurysm or hemorrhage related to ventriculostomy placement or systemic hemorrhagic events. Successful stent deployment was achieved in all cases without any significant technical difficulties.

There were two episodes of stent thrombosis. The first event was an asymptomatic non-occlusive stent thrombosis which developed during stent assisted coiling procedure in a 38-year-old woman (table 1, figure 3) with right paraparhalmic blister ruptured aneurysm (presenting H&H grade I and Fisher grade 3). In this case, early stent thrombosis occurred after multiple attempts were made to place the microcatheter into the aneurysm for suitable placement of coil. At that time it was decided to abort further attempts to catheterize the aneurysm and the microcatheter was withdrawn from the parent artery. Since the aneurysm was unsecured and the stent was non-occlusive with good antegrade flow, the operator decided to observe for 45 min to see the progression of stent thrombosis instead of administering a thrombolytic drug. The patient was given additional...
intravenous fluid and blood pressure was kept at the higher limit of normal. Within 20 min after withdrawal of the microcatheter, stent thrombosis began to resolve spontaneously and showed complete resolution in 45 min. The procedure was rescheduled in 6 days when successful placement of coil was achieved without any recurrent thrombosis. The patient was discharged home after 21 days with a GOS score of 5. The second event was observed on postoperative day 2 in a 46-year-old woman with H&H grade III and Fisher grade 3 who underwent stent assisted coiling of a ruptured basilar artery bifurcation aneurysm. Emergent intra-arterial administration of glycoprotein IIbIIIa receptor antagonist resulted in complete resolution of clot and symptoms. There was no mortality in our series. Good outcome was observed in 82% of patients (GOS score of 5 in 17 and GOS 4 in one) and poor outcome in 18% of patients (GOS 3 in four).

DISCUSSION
Stent assisted coiling of ruptured wide necked intracranial aneurysm patients has been included in the series of stent assisted coiling of intracranial aneurysms and the results have been conflicting. In a recent study of 40 patients with 41 acute ruptured aneurysms treated with 41 Neuroform stents, an intraoperative intravenous dose of glycoprotein IIbIIIa receptor antagonist (eptifibatide) was given intravenously during the procedure instead of oral antiplatelets prior to stent placement. However, a postoperative loading dose of clopidogrel and aspirin was provided. Intraoperative rupture of aneurysm was reported in 3/41 aneurysms while non-aneurysmal intracranial hemorrhage was observed in 2/40 cases. An intraoperative radiographic thromboembolic event was observed in four cases, three of which resolved after administration of eptifibatide. Ischemic stroke was observed in 5/40 cases, one immediate and four in a delayed fashion. In another study, 61 patients with acutely ruptured intracranial aneurysm were treated with stent assisted coiling. Most patients received intraprocedure acetylsalicylic acid. Some received heparin before stent deployment and some received heparin after stent deployment. Most received both aspirin and clopidogrel after the procedure. Technical success was observed in 72%. Intraoperative rupture of aneurysm was observed in 4/61 cases. Intraoperative thromboembolic events occurred in 9/61 cases. Mortality was observed in 20%. Good outcome was observed (GOS 5 and 4) in 69% of cases.

In comparing the results of our study with the most recent studies, (table 2), reporting only ruptured aneurysms, we observed no intraoperative rupture or postoperative hemorrhages in our series. In addition, compared with our series, the thromboembolic events, including stroke, were also higher in previous series, including a study that utilized...
Table 1  Clinical characteristics and outcome of patients who underwent stent assisted repair of ruptured wide necked intracranial aneurysms

<table>
<thead>
<tr>
<th>Age/sex</th>
<th>H&amp;H</th>
<th>Fisher</th>
<th>Location of aneurysm</th>
<th>Size (mm)</th>
<th>Time of EVD placement</th>
<th>Stent</th>
<th>Stent thrombosis</th>
<th>Immediate result of obliteration</th>
<th>12 months results</th>
<th>30 and 90 day GOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>71/M</td>
<td>I</td>
<td>1</td>
<td>BA bifurcation</td>
<td>9</td>
<td>No</td>
<td>Enterprise</td>
<td>No</td>
<td>Near complete</td>
<td>Pending</td>
<td>5</td>
</tr>
<tr>
<td>39/F</td>
<td>III</td>
<td>4</td>
<td>Left VA</td>
<td>4.4</td>
<td>After</td>
<td>Neuroform</td>
<td>No</td>
<td>Near complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>59/F</td>
<td>IV</td>
<td>1</td>
<td>Left paraclinoid ICA</td>
<td>5</td>
<td>After</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>48/F</td>
<td>III</td>
<td>4</td>
<td>BA bifurcation</td>
<td>9</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Complete</td>
<td>3</td>
</tr>
<tr>
<td>53/M</td>
<td>IV</td>
<td>4</td>
<td>Right MCA</td>
<td>13</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>42/F</td>
<td>I</td>
<td>1</td>
<td>Left ophthalmic artery</td>
<td>6</td>
<td>No</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Near complete</td>
<td>5</td>
</tr>
<tr>
<td>51/F</td>
<td>IV</td>
<td>4</td>
<td>BA bifurcation</td>
<td>6</td>
<td>before</td>
<td>Enterprise</td>
<td>No</td>
<td>Near complete</td>
<td>Pending</td>
<td>5</td>
</tr>
<tr>
<td>34/F</td>
<td>III</td>
<td>2</td>
<td>Right PICA</td>
<td>5</td>
<td>Before</td>
<td>Enterprise</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>38/F</td>
<td>I</td>
<td>1</td>
<td>Left ophthalmic artery</td>
<td>3</td>
<td>No</td>
<td>Enterprise</td>
<td>Yes</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>31/F</td>
<td>III</td>
<td>4</td>
<td>BA bifurcation</td>
<td>7</td>
<td>No</td>
<td>Enterprise</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>3</td>
</tr>
<tr>
<td>30/F</td>
<td>I</td>
<td>1</td>
<td>BA bifurcation</td>
<td>4</td>
<td>No</td>
<td>Enterprise</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>67/M</td>
<td>III</td>
<td>4</td>
<td>BA bifurcation</td>
<td>16</td>
<td>Before</td>
<td>Enterprise</td>
<td>No</td>
<td>Subtotal</td>
<td>Subtotal</td>
<td>4</td>
</tr>
<tr>
<td>42/F</td>
<td>I</td>
<td>2</td>
<td>PComA</td>
<td>5</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>33/F</td>
<td>I</td>
<td>4</td>
<td>PComA</td>
<td>8</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Near complete</td>
<td>3</td>
</tr>
<tr>
<td>67/F</td>
<td>II</td>
<td>2</td>
<td>MCA</td>
<td>30</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Subtotal</td>
<td>5</td>
</tr>
<tr>
<td>68/F</td>
<td>III</td>
<td>4</td>
<td>BA bifurcation</td>
<td>29</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Complete</td>
<td>3</td>
</tr>
<tr>
<td>52/F</td>
<td>I</td>
<td>2</td>
<td>PComA</td>
<td>6</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>46/F</td>
<td>III</td>
<td>3</td>
<td>BA bifurcation</td>
<td>9</td>
<td>Before</td>
<td>Neuroform</td>
<td>Yes</td>
<td>Near complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>36/F</td>
<td>II</td>
<td>2</td>
<td>BA bifurcation</td>
<td>7</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>57/F</td>
<td>I</td>
<td>2</td>
<td>BA bifurcation</td>
<td>8</td>
<td>No</td>
<td>Neuroform</td>
<td>No</td>
<td>Subtotal</td>
<td>Near complete</td>
<td>5</td>
</tr>
<tr>
<td>37/F</td>
<td>I</td>
<td>2</td>
<td>PComA</td>
<td>9</td>
<td>Before</td>
<td>Neuroform</td>
<td>No</td>
<td>Complete</td>
<td>Complete</td>
<td>5</td>
</tr>
<tr>
<td>59/F</td>
<td>I</td>
<td>2</td>
<td>BA bifurcation</td>
<td>15</td>
<td>No</td>
<td>Enterprise</td>
<td>No</td>
<td>Subtotal</td>
<td>Near complete</td>
<td>5</td>
</tr>
</tbody>
</table>

After, after endovascular procedure; Before, before endovascular procedure; BA, basilar artery; EVD, extraventricular drainage; GOS, Glasgow Outcome Scale (GOS 5, independent with no symptoms; GOS 1, dead); H&H, Hunt and Hess grade; ICA, internal carotid artery; MCA, middle cerebral artery; PComA, posterior communication artery; PICA, posterior inferior cerebellar artery; VA, vertebral artery.

Figure 3  (A) A 38-year-old women presented with subarachnoid hemorrhage Hunt and Hess grade I and Fisher grade 1 due to a ruptured left ophthalmic internal carotid artery (ICA) aneurysm and planned to undergo stent assisted repair. A second aneurysm at the cavernous ICA was also discovered. (B) Later view angiogram of the left ICA demonstrated asymptomatic non-occlusive stent thrombosis in the ophthalmic and cavernous portions of the left ICA. (C) Lateral view angiogram of the left ICA demonstrates progressive resolution of stent thrombosis in the ophthalmic and cavernous ICA. (D) Patient underwent repeat procedure with placement of a second stent and successful coiling of the aneurysm. (E) Lateral view angiogram of the left ICA demonstrated successful coiling of the aneurysms.
Table 2 Comparison of the current study with previous studies that treated ruptured wide necked aneurysms using stent assisted coiling of ruptured aneurysms.

<table>
<thead>
<tr>
<th>Study</th>
<th>No of patients</th>
<th>Antiplatelet regimen</th>
<th>Intraoperative rupture (n (%))</th>
<th>Intracerebral hemorrhage (n (%))</th>
<th>Thromboembolic event</th>
<th>Stroke</th>
<th>EVD related complications</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Janikovitz</td>
<td>41</td>
<td>Intravenous glycoprotein IIbIIIa antagonist followed by post- procedural aspirin and clopidogrel. Standard use of heparin during procedure was maintained</td>
<td>3 (4.5)</td>
<td>2 (5)</td>
<td>Total = 9 (10%)</td>
<td>5 with good outcome</td>
<td>Total events = 9 catheter track puncture hemorrhage = 7 (3 clinically significant). Large hemorrhage = 2 (symptomatic in 1)</td>
<td>Described as good, but no clear specification was provided</td>
</tr>
<tr>
<td>Thantinen</td>
<td>61</td>
<td>No standard antiplatelet regimen. Some received intraoperative acetylsalicylate and some received intraprocedural heparin to obtain an activated coagulation time of 1.5–2 times baseline prior to stent deployment.</td>
<td>4 (7)</td>
<td></td>
<td>Total events = 7 (11%)</td>
<td>Not described</td>
<td>Not described</td>
<td>Mortality 20%. Good outcome in 89% (GOS 5 and 4)</td>
</tr>
<tr>
<td>Lodi (current study)</td>
<td>22</td>
<td>Loading dose of 300 mg clopidogrel and aspirin at least 2 h prior to stent placement followed by 75 mg of clopidogrel and 325 mg aspirin daily for 4 weeks. All patients received intravenous heparin to obtain an activated coagulation time of 1.5–2 times baseline prior to stent deployment.</td>
<td>0</td>
<td>0</td>
<td>Total events = 2</td>
<td>Intraoperative non-occlusive stent thrombosis, 1 of which resolved spontaneously. Delayed symptomatic presentation was observed in 1 required intraarterial administration of GPIIbIIIa receptor antagonist which resulted in complete resolution</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

EVD, extraventricular drainage; GOS, Glasgow Outcome Scale.
in stent assisted coiling of ruptured intracranial wide necked aneurysm. Therefore, standard antiplatelet regimens should not be withheld prior to stent assisted coiling of carefully selected ruptured wide necked aneurysms. A larger prospective and blinded study looking at the same outcomes in a similar cohort is needed to replicate and confirm our results.

Competing interests None.

Ethics approval Institutional Review Board approval was obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

Correction


The author name F C Alberquerque should have been spelt FC Albuquerque.

Muhammad Shazam Hussain was missing from the author list. The list now reads: K A Blackham, P M Meyers, T A Abruzzo, F C Albuquerque, D Fiorella, J Fraser, D Frei, C D Gandhi, D V Heck, J A Hirsch, D P Hsu, M Shazam Hussain, M Jayaraman, S Narayanan, C Prestigiacomo, J L Sunshine, on behalf of the Society for NeuroInterventional Surgery.